Biomarkers identification for the progression from pre-diabetes to T2D
Research type
Research Study
Full title
Investigating plasma biomarker molecules associated with the progression of prediabetes to overt type 2 diabetes
IRAS ID
245301
Contact name
Richard Mackenzie
Contact email
Sponsor organisation
University of Roehampton Ethics Committee Chair, University of Roehampton
Clinicaltrials.gov Identifier
LSC 20/ 311, University of Roehampton Ethics
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Research tells us that there are an estimate 7 million people in the UK living with pre-diabetes (Diabetes UK, Report 2009). The increasing number of new cases of pre-diabetes presents a global health concern due to funding implications.
The progression from pre-diabetes to overt type 2 diabetes is often characterised by a reduction in insulin secretion (or β-cell dysfunction). Whilst inflammation may contribute to β-cell dysfunction, a complete picture is still lacking. The proposed research will help develop a more complete understanding of the molecules that may trigger β-cell failure, a process that often connects pre-diabetes to overt diabetes. If we can identify key factors that are implicated in causing β-cell failure then we can use these as potential biomarkers to aggressively target those at-risk individuals, therefore preventing (potentially) the development of habitual hyperglycaemic and type 2 diabetes.
The aims of this project are;
1. Run large-scale proteomics and metabolomics analysis in pre-diabetic individuals to determine possible biomarker molecules.
2. Use measures and / or classifications of insulin resistance and diabetes (i.e. β-cell function and Disposition Index) to establish whether particular metabolic and / or proteomic signatures (aim 1) are associated with the development of pre-diabetes.
3. To determine if the possible metabolite or protein profile changes are associated with the progression or regression of pre-diabetes from baseline (0 month) to the end of the National Diabetes Prevention Programme (9 month).Diabetes UK. (2009). Preventing the type 2 diabetes epidemic, https://www.diabetes.org.uk/professionals/position-statements-reports
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
20/EE/0250
Date of REC Opinion
12 Nov 2020
REC opinion
Further Information Favourable Opinion